Oncology Hero

11 new oncology trials approved in Europe

Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe.

A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients

Sponsor: Centre Leon Berard

Phase: 2

Interested in offering this trial to suitable patients?

PD-1 blockade alone versus in combination with chemotherapy as first line therapy in females with advanced NSCLC & PD-L1 expression ≥50%

Sponsor: Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Phase: 3

Interested in offering this trial to suitable patients?

Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer with a High Tumor Burden

Sponsor: AIO-Studien gGmbH

Phase: 3

Interested in offering this trial to suitable patients?

SNIPER-LTFU: Long-term follow-up study of patients administered with RR001 in the interventional Parent SNIPER study

Sponsor: Eir Biotherapies S.r.l.

Phase:

Interested in offering this trial to suitable patients?

HOVON 185: Pharmacokinetic boosting of ibrutinib with ritonavir in patients with chronic lymphocytic leukemia, lymphoplasmacytic- and mantle cell lymphoma

Sponsor: Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Phase: 2

Interested in offering this trial to suitable patients?

Neoadjuvant trastuzumab, pertuzumab and zongertinib without chemotherapy in HER2-positive breast cancer: the TRAIN-5 study

Sponsor: Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Phase: 1

Interested in offering this trial to suitable patients?

Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Sponsor: Fundacion PETHEMA

Phase: 2

Interested in offering this trial to suitable patients?

A single-arm pilot study to investigate tumor absorbed dose dynamics and feasibility of pre-treatment dosimetry with [177Lu]Lu-PSMA-I&T in male participants aged ≥18 years with metastatic castration-resistant prostate cancer

Sponsor: Universitetssykehuset Nord-Norge HF

Phase: 2

Interested in offering this trial to suitable patients?

A Randomized, Open-label, Phase 3 Study of Setidegrasib (ASP3082) versus Docetaxel in Participants with KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on or After Platinum-based Chemotherapy and Checkpoint Inhibitor Therapy (CPI)

Sponsor: Astellas Pharma Global Development Inc.

Phase: 3

Not accepting new sites

A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma (RASolute 309)

Sponsor: Revolution Medicines Inc.

Phase: 3

Not accepting new sites

An open label, multi-center alpelisib roll-over study to assess long-term safety in participants who have completed a Novartis sponsored alpelisib (BYL719) study and are judged by the Investigator to benefit from continued treatment with alpelisib.

Sponsor: Novartis Pharma AG

Phase: 2

Not accepting new sites

Oncology Hero Trial Feed connects oncology professionals with relevant clinical trials.

For qualified healthcare and research professionals. Registration expresses investigator interest; it is not patient enrollment.

Oncology Hero

11 new oncology trials approved in Europe

11 new oncology trials approved in Europe

A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients

PD-1 blockade alone versus in combination with chemotherapy as first line therapy in females with advanced NSCLC & PD-L1 expression ≥50%

Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer with a High Tumor Burden

SNIPER-LTFU: Long-term follow-up study of patients administered with RR001 in the interventional Parent SNIPER study

HOVON 185: Pharmacokinetic boosting of ibrutinib with ritonavir in patients with chronic lymphocytic leukemia, lymphoplasmacytic- and mantle cell lymphoma

Neoadjuvant trastuzumab, pertuzumab and zongertinib without chemotherapy in HER2-positive breast cancer: the TRAIN-5 study

Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma

A single-arm pilot study to investigate tumor absorbed dose dynamics and feasibility of pre-treatment dosimetry with [177Lu]Lu-PSMA-I&T in male participants aged ≥18 years with metastatic castration-resistant prostate cancer

A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma (RASolute 309)

An open label, multi-center alpelisib roll-over study to assess long-term safety in participants who have completed a Novartis sponsored alpelisib (BYL719) study and are judged by the Investigator to benefit from continued treatment with alpelisib.

8 new oncology trials approved in Europe

8 new oncology trials approved in Europe

15 new oncology trials approved in Europe